Author details

Full Name

Rochelle Bagatell

Affiliation

ORCID

Career Start Year

1999

Papers

119

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36458672	Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020.	Pediatr Blood Cancer	2023
36206505	Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.	Journal of Clinical Oncology	2023
36897628	Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments.	J Pediatr Hematol Oncol	2023
36822669	KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.	J Immunother Cancer	2023
37458162	Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.		2023
37199022	Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.		2023
36749880	Impact of Genomic and Clinical Factors on Outcome of Children â¿¥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.		2023
35235547	Guideline for Children With Cancer Receiving General Anesthesia for Procedures and Imaging.	J Pediatr Hematol Oncol	2022
35839426	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.	J Clin Oncol	2022
35836290	Novel ATXN1/ATXN1L::NUTM2A fusions identified in aggressive infant sarcomas with gene expression and methylation patterns similar to CIC-rearranged sarcoma.	Acta Neuropathol Commun	2022
35739269	Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.	Nat Med	2022
35665495	Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.	Cancer	2022
34383370	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.	Pediatric Blood and Cancer	2021
33677616	A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.	Cancer Chemotherapy and Pharmacology	2021
34152837	Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials.	Journal of Clinical Oncology	2021
33504555	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.	Clin Cancer Res	2021
33823167	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.	Transplant Cell Ther	2021
34028986	A safety and feasibility trial of <sup>131</sup> I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.	Pediatr Blood Cancer	2021
33818884	Neuroblastoma.	Pediatric Blood and Cancer	2021
34319759	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.	J Clin Oncol	2021
32769567	More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma.	J Pediatr Hematol Oncol	2021
33227816	Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.	J Natl Cancer Inst	2021
34964003	Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor.	JCO Precis Oncol	2021
32735385	Trends in conditional survival and predictors of late death in neuroblastoma.	Pediatric Blood and Cancer	2020
32079986	Role of Metastatic Site Irradiation in Pediatric Patients With Metastatic Ewing Sarcoma.	Journal of Pediatric Hematology/Oncology	2020
31584705	Unrealistic parental expectations for cure in poor-prognosis childhood cancer.	Cancer	2020
32360991	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer.	Journal of Pain and Symptom Management	2020
32343642	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.	J Clin Oncol	2020
31612589	The ganglioside G as a circulating tumor biomarker for neuroblastoma.	Pediatric Blood and Cancer	2020
32453441	Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study.	Cancer	2020
32492633	Association of heterogeneous MYCN amplification with clinical features, biological characteristicsÂ and outcomes in neuroblastoma: A report from the Children's Oncology Group.	Eur J Cancer	2020
31335288	Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway.	Pediatr Dev Pathol	2019
30480556	Advances in neuroblastoma therapy.	Current Opinion in Pediatrics	2019
30479064	The challenge of defining "ultra-high-risk" neuroblastoma.	Pediatr Blood Cancer	2019
31133068	Clinical utility of custom-designed NGS panel testing in pediatric tumors.	Genome Med	2019
31454025	Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision Medicine.	JAMA - Journal of the American Medical Association	2019
30968531	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.	Pediatr Blood Cancer	2019
30738983	Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma.	Int J Radiat Oncol Biol Phys	2019
31115156	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.	Pediatr Blood Cancer	2019
31255796	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers.	J Mol Diagn	2019
30947024	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).	European Journal of Cancer	2019
29528977	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia.	Pediatr Crit Care Med	2018
28748602	VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.	Pediatr Blood Cancer	2018
29058370	Proton therapy for pediatric head and neck malignancies.	Pediatric Blood and Cancer	2018
29932284	Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor.	Pediatr Blood Cancer	2018
30070014	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.	Pediatr Blood Cancer	2018
30093449	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.	Clin Cancer Res	2018
29445029	Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.	Oncologist	2018
28146330	Using electronic medical record data to report laboratory adverse events.	Br J Haematol	2017
28642300	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.	Haematologica	2017